The nitric oxide pathway in pulmonary arterial hypertension: pathomechanism, biomarkers and drug targets
The altered Nitric Oxide (NO) pathway in the pulmonary endothelium leads to increased
vascular smooth muscle tone and vascular remodelling, and thus contributes to the …
vascular smooth muscle tone and vascular remodelling, and thus contributes to the …
[HTML][HTML] Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease
Treating patients hospitalised with acute exacerbations of chronic obstructive pulmonary
disease (COPD) usually involves administering systemic corticosteroids. The many …
disease (COPD) usually involves administering systemic corticosteroids. The many …
Nitric Oxide as a Diagnostic and Therapeutic Tool in Respiratory Diseases
K Gulati, SK Thokchom, A Ray - Nitric Oxide: From Research to …, 2023 - Springer
Nitric oxide (NO) is a gasotransmitter that plays a vital role in diverse biological processes.
NO is a fundamental component in regulating cardiovascular functions, smooth muscle tone …
NO is a fundamental component in regulating cardiovascular functions, smooth muscle tone …
[PDF][PDF] Using blood eosinophil count as a biomarker to guide corticosteroid treatment for chronic obstructive pulmonary disease. Diagnostics. 2021; 11 (2): 236
Treating patients hospitalised with acute exacerbations of chronic obstructive pulmonary
disease (COPD) usually involves administering systemic corticosteroids. The many …
disease (COPD) usually involves administering systemic corticosteroids. The many …
Current Approaches to COPD in 2019
A Corlăteanu - Current Respiratory Medicine Reviews, 2019 - ibn.idsi.md
Rezumat Chronic Obstructive Pulmonary Disease (COPD) remains the fourth leading cause
of chronic morbidity and mortality at the global level, and it represents a major problem for …
of chronic morbidity and mortality at the global level, and it represents a major problem for …
[PDF][PDF] downloaded from the King's Research Portal at https://kclpure. kcl. ac. uk/portal
T Harries - 2021 - kclpure.kcl.ac.uk
Background The evidence that patients with mild or moderate COPD are likely to benefit
from inhaled corticosteroid (ICS) therapy by suffering fewer exacerbations is equivocal …
from inhaled corticosteroid (ICS) therapy by suffering fewer exacerbations is equivocal …